A Phase 4 interventional study of NeuroAiD in Spinal Cord Injury, sponsored by Moleac Pte Ltd.. Completed at 1 site in Malaysia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-15.
Sponsored by Moleac Pte Ltd. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
SATURN investigates the promising role of NeuroAiD in patients with spinal cord injury and will provide important information on the feasibility of conducting larger controlled trials.
SATURN is a prospective cohort study of patients with moderately-severe to severe spinal cord injury, defined as American Spinal Injury Association Impairment Scale A and B, who are treated with open-label NeuroAiD for 6 months in addition to standard care and followed for 24 months. Anonymized data will be prospectively collected at baseline and months 1, 3, 6, 12, 18, and 24 using a secured online system and will include information on demographics, main diagnostics, neurological and functional state, treatment compliance, concomitant therapies, and side effects, if any.
2,028 studies on the registry are indexed under Spinal Cord Injuries; 538 are open to participants now.
This study's enrollment of 30 is above the median of 24 across 1,634 interventional studies indexed under Spinal Cord Injuries.
Browse Spinal Cord Injuries studies →Moleac Pte Ltd. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NeuroAiD
Drug: NeuroAiD
Also known as: MLC601, MLC901
Spinal cord injury severity based on American Spinal Injury Association Impairment Scale
Time frame: 6 months
Motor recovery based on American Spinal Injury Association Impairment Scale motor score
Time frame: 6 months
Number of patients experiencing adverse events
Adverse events as individual events and according to organ system, severity, and relatedness
Time frame: 6 months
Spinal cord injury severity based on American Spinal Injury Association Impairment Scale
Time frame: 1, 3, 12, 18, 24 months
Motor recovery based on American Spinal Injury Association Impairment Scale motor score
Time frame: 1, 3, 12, 18, 24 months
Sensory recovery based on American Spinal Injury Association Impairment Scale sensory score
Time frame: 1, 3, 6, 12, 18, 24 months
Functional state based on Spinal Cord Independence Measure
Time frame: 1, 3, 6, 12, 18, 24 months
Quality of life based on Short Form-8 Health Survey
Time frame: 1, 3, 6, 12, 18, 24 months
Ran from Apr 2015 to primary completion in Sep 2023, 101 months.
Of 19 phase 4 interventional studies under Spinal Cord Injuries, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's 101 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Neuroaid
Moleac Pte Ltd.